RLY-2608 has rare blockbuster potential, but a global partnership might be the best path to realizing it. Pipeline guidance suggests the entire breast cancer portfolio could become a packaged deal in 2025.

The company's prized asset delivered a no-doubter data readout that crushed prior-gen comparisons, but Scorpion Therapeutics quickly cemented itself as a next-gen competitor.

The precommercial drug developer has scheduled the most important data readout in its history for Monday, September 6 before the market opens. Here's how to interpret the results.

Revenue has more than doubled since the beginning of fiscal 2022. However, the number of customers has only grown by 28% in that span. There are advantages and disadvantages to the trend.

The new premium offerings, which boast a faster turnaround time than the company's standard synthetic genes, surged the order backlog of the synthetic genes segment to $44.9 million -- an increase of 54% from the fiscal first quarter.

The DNA synthesis leader is growing revenue at a solid clip and improving operating efficiency. Although operating income is a distant milestone, Express Genes should accelerate its arrival.

The drug developer will have three significant data readouts for RLY-4008 and RLY-2608. Unfortunately for impatient investors, they're all slated for the second half of the year.

The pre-commercial drug developer previously expected to commercialize its lead drug candidate in a rare bile duct cancer ahead of other tumor types, but will now pursue a broader tumor-agnostic approval.

The ReDiscover study evaluating RLY-2608 demonstrated industry-leading safety and tolerability, but initial efficacy data spooked investors. Wall Street is assuming the asset risks lagging the competitive landscape when combined with the chemotherapy drug fulvestrant.

Solt DB Invest previously assigned a significantly higher probability of success (POS) to the pipeline at Relay Therapeutics than the industry average. We're increasing that metric in our modeling, which results in a higher Margin of Safety range.

Solt DB Invest recommended closing positions in Twist Bioscience after a short report from Scorpion Capital published on Tuesday, November 15. Here are the reasons why I came to that conclusion and suspended coverage.

Solt DB Invest is recommending to close positions in Twist Bioscience. The quality control issues described in the short report, as well as surging operating expenses and loss of competitive positioning, can be corroborated with discussions I've had with customers.

(This is where the idea for Open Coverage was born.) More detailed data for RLY-4008 and a new collaboration with Foundation Medicine (Roche) to develop a companion diagnostic for the asset.

This article explores an abstract for a poster and data presentation at the European Society of Medical Oncology (ESMO) Congress 2022.

I'm not confident the recent rally in the biotech sector can be trusted. I'm confident Twist Bioscience has significant valuation risk near current levels.

Let's circle back around to the Relay Therapeutics pipeline update from June 27.